[ad_1]
An international group of scientists has succeeded in producing a new antibody based on the immune system of llamas, with which they hope to develop an effective vaccine against all types of influenza, according to a study published in the journal Science.
Mixing The researchers were able to generate a vaccine offering long-lasting protection against two strains of influenza A and B.
The experiment was successfully tested in mice infected with lethal doses of influenza virus . influenza.
Based on the immune system of lamas, an animal that abounds in Argentina and in countries like Peru and Bolivia, scientists have been able to cure mice and hope that these results open up a new possibility to find a vaccine for humans.
The research was directed by Nick Laursen Scripps Research Institute La Jolla (California, USA) and, according to the results published in the latest issue of Science, the vaccine was developed to prevent infection of several strains of influenza.
But what excited the researchers most was that they were able to protect older, immunodeficient mice infected with high doses of the H1N1 strain. known as "influenza A".
According to results published in Science, research is focused on the development of a "muldominio" antibody, [194590]. 03] that is to say that it offers protection against different types of flu at the same time
The experiment directly attacked hemagglutinin, a protein of the outer layer of the virus, which eventually made it adhere to the cells of the respiratory system.
The researchers decided to use flames because of the special features of their immune systems that make it easier for them to manipulate antibodies because they are much smaller than humans and provide access to more distant places.
It is still too early to determine whether these gains are applicable in humans . They point out that there is a door open to find a flu vaccine, one of the most difficult to attack because of the number of strains it has and its immune potential. continuous mutation.
The antibodies that they developed, the MD3606, could primarily be used to protect the most vulnerable population, such as people over 65 years old.
"The rapid appearance of protection, as well as the unprecedented cross-reactivity of MD3606 (the developed antibody) vis-à-vis strains of avian influenza, offer also the possibility of using this approach prophylactically ", . study, which also participated in the University of Pennsylvania. USA
[ad_2]
Source link
